恒瑞医药: 恒瑞医药董监高减持股份计划公告

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a senior executive of Jiangsu Hengrui Medicine Co., Ltd. due to personal financial needs, which involves selling up to 0.007% of the company's total shares within a specified timeframe [1][2]. Group 1: Shareholder Information - The shareholder involved in the reduction plan is Sun Jieping, a director and senior vice president of the company, who currently holds 1,907,032 shares, representing 0.029% of the total shares [1]. - The shares held by Sun Jieping were acquired through equity incentives (1,883,032 shares) and other means (24,000 shares) [1]. Group 2: Reduction Plan Details - The planned reduction involves selling no more than 476,700 shares, which is up to 0.007% of the total share capital [1]. - The reduction will occur through centralized bidding from July 7, 2025, to October 6, 2025, with the selling price determined by market conditions at the time of sale [1]. - The reason for the reduction is stated as personal financial needs [1]. Group 3: Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law and the Management Rules for Share Reduction by Shareholders of Listed Companies [2]. - The company will ensure that the reduction is conducted in accordance with the regulations and will fulfill its information disclosure obligations during the process [2].